Acute and long-term hemodynamic response to low-dose enoximone in refractory heart failure
- 1 November 1989
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 3 (6) , 913-918
- https://doi.org/10.1007/bf01869581
Abstract
Enoximone possesses both positive inotropic and vasodilatory properties. In heart failure, doses varying between 3 mg/kg and 6 mg/kg produce a beneficial acute hemodynamic response but have been associated with significant side effects. Little is known about the long-term hemodynamic efficacy of this agent. To assess whether a lower dose of enoximone could produce both acute and long-term hemodynamic benefits and be better tolerated, 15 patients with refractory heart failure were given enoximone 100 mg every 8 hours (mean dose, 1.7 mg/kg). The cardiac index, pulmonary capillary wedge pressure, pulmonary artery pressure, right atrial pressure, systemic vascular resistance, pulmonary vascular resistance, and stroke volume index all improved significantly during the first 24 hours. The systemic blood pressure and heart rate did not alter appreciably during this period. Five of six patients remaining on therapy at 6 months had a follow-up hemodynamic study. Sustained improvement was seen in the cardiac index, pulmonary capillary wedge pressure, and pulmonary artery pressure when compared to baseline (all p<0.05). A satisfactory trend, which did not reach statistical significance, was noted in the right atrial pressure (p=0.09) and stroke volume index (p=0.06). Diarrhea occurred in one patient. These findings indicate that enoximone has a beneficial acute and long-term hemodynamic effect at a low dose that is clinically well tolerated.Keywords
This publication has 20 references indexed in Scilit:
- The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmiasAmerican Heart Journal, 1989
- Hemodynamic, antiischemic, and neurohumoral effects of enoximone in patients with coronary artery diseaseAmerican Heart Journal, 1989
- Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathyThe American Journal of Cardiology, 1986
- Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.Circulation, 1985
- Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failureAmerican Heart Journal, 1984
- Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failureThe American Journal of Cardiology, 1984
- Hemodynamic Effects of MDL 17,043, a New Cardiotonic Agent, in Patients with Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1983
- The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.Circulation, 1983
- Hemodynamic Assessment of AmrinoneNew England Journal of Medicine, 1978
- Approaches to Sudden Death from Coronary Heart DiseaseCirculation, 1971